Maze Therapeutics, Inc. — Form 10-Q
Filed August 11, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 18/100
What the filing says
Maze Therapeutics amended its Non-Employee Director Compensation Policy effective June 1, 2026. The policy establishes annual cash retainers ($40,000 base board fee plus committee fees ranging $5,000–$20,000) and equity grants: Initial Award of up to 36,000 shares or $750,000 fair value upon appointment (vesting over 3 years monthly), and Annual Award of up to 18,000 shares or $375,000 fair value at each stockholder meeting (vesting within 1 year). No material changes to compensation amounts or terms are disclosed in this excerpt.
Why this rating
Routine board compensation policy amendment. Dollar amounts are standard for public biotech of this size; no stated changes to prior policy disclosed here.
See more from August 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.